Fertility testing in the UK is beginning to shift towards a more streamlined approach. Instead of navigating multiple appointments, referrals, and long waiting times, couples can now complete key tests at home and attend their first clinic consultation with results already available.
Sapyen, a fertility diagnostics company working alongside IVF clinics such as Avenues, has introduced a combined testing solution that integrates male fertility hormone testing, female AMH testing, and laboratory semen analysis into one coordinated pathway.
The process is designed to be clear and accessible. A male hormone panel assesses testosterone, FSH, and LH, while a female AMH test offers an early indication of ovarian reserve. Each test is priced at £69. These can be combined with a £149 semen analysis, which is carried out in a laboratory using samples collected at home.
What distinguishes this approach is the way the tests are brought together. Couples can now complete a clinically meaningful fertility assessment before their first appointment, enabling consultations to begin with data rather than initial uncertainty.
This change has important implications. Fertility pathways are often delayed by fragmented testing and limited early involvement from male partners. By engaging both individuals from the outset, clinicians are able to move more efficiently from investigation to treatment decisions.
The inclusion of hormone testing for men is particularly valuable. While male factors are involved in around half of infertility cases, assessments have traditionally focused on sperm alone. Combining semen analysis with hormone profiling provides a more complete picture of male reproductive health.
For women, AMH testing offers early insight that can influence planning and expectations before treatment begins. Supporting this model is Sapyen’s ability to transport semen samples to laboratories without the usual time constraints, allowing at-home collection without compromising analysis quality.
For clinics, integration is straightforward, with results delivered in standard formats that fit easily into existing systems. For patients, the process is simpler, quicker, and involves fewer delays.
The result is a new starting point for fertility care — one where both partners are assessed together, clinicians gain early clarity, and decisions can be made more confidently from the first consultation.
